2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2612

Utility of Infiltration with Steroids in Dactilitis. Is the Infiltration Guided By Ecography Better THAN Conventional?
Abstract Number: 2613

Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Abstract Number: 2614

The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
Abstract Number: 2615

The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
Abstract Number: 2616

The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry
Abstract Number: 2617

Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Abstract Number: 2618

Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
Abstract Number: 2619

Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Abstract Number: 2620

The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort
Abstract Number: 2621

Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
Abstract Number: 2622

Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care
Abstract Number: 2623

Efficacy of TNF Inhibitors and Predictive Factors of Clinical Presentation in Patients with Psoriatic Arthritis
Abstract Number: 2624

Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
Abstract Number: 2625

TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Abstract Number: 2626

Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].